Trial watch

References

• Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005; 18:21 - 5; PMID: 16200144
   PubMedGoogle Scholar
• Smith KA. Edward jenner and the small pox vaccine. Front Immunol 2011; 2:21; http://dx.doi.org/10.3389/fimmu.2011.00021; PMID: 22566811
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269 - 77; http://dx.doi.org/10.1038/nm0303-269; PMID: 12612576
   PubMed Web of Science ®Google Scholar
• Smith KA. Louis pasteur, the father of immunology?. Front Immunol 2012; 3:68; http://dx.doi.org/10.3389/fimmu.2012.00068; PMID: 22566949
   PubMed Web of Science ®Google Scholar
• Plett PC. [Peter Plett and other discoverers of cowpox vaccination before Edward Jenner]. Sudhoffs Arch 2006; 90:219 - 32; PMID: 17338405
   PubMedGoogle Scholar
• Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980; 303:1263 - 73; http://dx.doi.org/10.1056/NEJM198011273032204; PMID: 6252467
   PubMed Web of Science ®Google Scholar
• Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003; 79:672 - 80; PMID: 14707241
   PubMed Web of Science ®Google Scholar
• Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011; 2011:609579; http://dx.doi.org/10.1155/2011/609579; PMID: 22110526
   PubMed Web of Science ®Google Scholar
• Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986; 256:3117 - 24; http://dx.doi.org/10.1001/jama.1986.03380220083027; PMID: 3491225
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907 - 13; http://dx.doi.org/10.1001/jama.1994.03510360033032; PMID: 8120958
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology 2012; 1; In press http://dx.doi.org/10.4161/onci.20931
   Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327:1345 - 50; http://dx.doi.org/10.1126/science.1177319; PMID: 20223979
   PubMed Web of Science ®Google Scholar
• Finn OJ. Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol 2004; 16:127 - 9; http://dx.doi.org/10.1016/j.coi.2004.02.006; PMID: 15023402
   PubMed Web of Science ®Google Scholar
• Burgio GR. Commentary on the biological self: Toward a “Biological Ego”. From Garrod’s “chemical individuality” to Burnet’s “self”. Thymus 1990; 16:99 - 117; PMID: 2256127
   PubMedGoogle Scholar
• Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Annu Rev Immunol 1986; 4:119 - 45; http://dx.doi.org/10.1146/annurev.iy.04.040186.001003; PMID: 3518743
   PubMed Web of Science ®Google Scholar
• Janeway C. Immunogenicity signals 1,2,3 ... and 0. Immunol Today 1989; 10:283 - 6; http://dx.doi.org/10.1016/0167-5699(89)90081-9; PMID: 2590379
   PubMedGoogle Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991 - 1045; http://dx.doi.org/10.1146/annurev.iy.12.040194.005015; PMID: 8011301
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301 - 5; http://dx.doi.org/10.1126/science.1071059; PMID: 11951032
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643 - 7; http://dx.doi.org/10.1126/science.1840703; PMID: 1840703
   PubMed Web of Science ®Google Scholar
• Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993; 14:536 - 8; http://dx.doi.org/10.1016/0167-5699(93)90183-L; PMID: 8274196
   PubMedGoogle Scholar
• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1:209 - 19; http://dx.doi.org/10.1038/35105075; PMID: 11905830
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337 - 65; http://dx.doi.org/10.1146/annurev.iy.12.040194.002005; PMID: 8011285
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11:263 - 70; http://dx.doi.org/10.1016/S1074-7613(00)80101-6; PMID: 10514004
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281 - 7; http://dx.doi.org/10.1016/S1074-7613(00)80028-X; PMID: 10204484
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267 - 96; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609; PMID: 17134371
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83 - 117; http://dx.doi.org/10.1146/annurev.immunol.021908.132544; PMID: 19007331
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
   PubMed Web of Science ®Google Scholar
• Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10:707 - 19; http://dx.doi.org/10.1038/nrc2888; PMID: 20865011
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550 - 60; http://dx.doi.org/10.1038/nrc2886; PMID: 20592731
   PubMed Web of Science ®Google Scholar
• Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010; 10:878 - 89; http://dx.doi.org/10.1038/nrc2961; PMID: 21102637
   PubMed Web of Science ®Google Scholar
• Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88:1025 - 9; http://dx.doi.org/10.1097/TP.0b013e3181b9d918; PMID: 19855249
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134:1385 - 95; http://dx.doi.org/10.1053/j.gastro.2008.02.058; PMID: 18471515
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci 2009; 100:1935 - 42; http://dx.doi.org/10.1111/j.1349-7006.2009.01256.x; PMID: 19604246
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915 - 27; http://dx.doi.org/10.1056/NEJMoa061741; PMID: 17494925
   PubMed Web of Science ®Google Scholar
• Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med 2007; 356:1908 - 10; http://dx.doi.org/10.1056/NEJMp078053; PMID: 17494923
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al, HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705 - 19; http://dx.doi.org/10.4161/hv.5.10.9518; PMID: 19684472
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford D. A minute chromosome in chronic granulocytic leukemia. Science 1960; 132:1497
   Web of Science ®Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290 - 3; http://dx.doi.org/10.1038/243290a0; PMID: 4126434
   PubMed Web of Science ®Google Scholar
• Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011; 110:107 - 39; http://dx.doi.org/10.1016/B978-0-12-386469-7.00005-0; PMID: 21704230
   PubMed Web of Science ®Google Scholar
• Liu ET. Functional genomics of cancer. Curr Opin Genet Dev 2008; 18:251 - 6; http://dx.doi.org/10.1016/j.gde.2008.07.014; PMID: 18691651
   PubMed Web of Science ®Google Scholar
• Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 1996; 8:289 - 93; http://dx.doi.org/10.1006/smim.1996.0037; PMID: 8956457
   PubMedGoogle Scholar
• Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica 2006; 91:48 - 55; PMID: 16434370
   PubMed Web of Science ®Google Scholar
• Fossum B, Gedde-Dahl T 3rd, Breivik J, Eriksen JA, Spurkland A, Thorsby E, et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp). Int J Cancer 1994; 56:40 - 5; http://dx.doi.org/10.1002/ijc.2910560108; PMID: 7903287
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Madrigal A, Travers P, Dodi AI. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors. Cancer Immunol Immunother 2009; 58:1449 - 57; http://dx.doi.org/10.1007/s00262-009-0703-x; PMID: 19360407
   PubMed Web of Science ®Google Scholar
• Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53:3257 - 61; PMID: 7686815
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357 - 65; http://dx.doi.org/10.1084/jem.183.4.1357; PMID: 8666894
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9:4247 - 54; PMID: 14519652
   PubMed Web of Science ®Google Scholar
• Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005; 23:5099 - 107; http://dx.doi.org/10.1200/JCO.2005.03.158; PMID: 15983396
   PubMed Web of Science ®Google Scholar
• Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 2012; 11:133 - 44; http://dx.doi.org/10.1586/erv.11.177; PMID: 22309662
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9:675 - 81; http://dx.doi.org/10.1038/nrc2717; PMID: 19701243
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C:373 - 89; PMID: 4142565
   PubMedGoogle Scholar
• Siskind GW, Arreaza E. Network regulation of the immune response. Allergy Proc 1989; 10:387 - 91; http://dx.doi.org/10.2500/108854189778935872; PMID: 2697632
   PubMedGoogle Scholar
• Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 1972; 69:1540 - 4; http://dx.doi.org/10.1073/pnas.69.6.1540; PMID: 4113870
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007; 26:3594 - 602; http://dx.doi.org/10.1038/sj.onc.1210371; PMID: 17530013
   PubMed Web of Science ®Google Scholar
• Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, Goodman MF, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26:481 - 511; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090236; PMID: 18304001
   PubMed Web of Science ®Google Scholar
• Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc 1977; 36:2268 - 71; PMID: 69552
   PubMedGoogle Scholar
• Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5:1171 - 7; http://dx.doi.org/10.1038/13928; PMID: 10502821
   PubMed Web of Science ®Google Scholar
• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517 - 22; http://dx.doi.org/10.1056/NEJM198203043060906; PMID: 6173751
   PubMed Web of Science ®Google Scholar
• Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2:1038 - 41; http://dx.doi.org/10.1038/nm0996-1038; PMID: 8782465
   PubMed Web of Science ®Google Scholar
• Mufson RA. Tumor antigen targets and tumor immunotherapy. Front Biosci 2006; 11:337 - 43; http://dx.doi.org/10.2741/1801; PMID: 16146735
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62:3521 - 9; PMID: 12067999
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Boeckers P, Engers R, Boelke E, Bas M, Greve J, et al. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. J Transl Med 2011; 9:168; http://dx.doi.org/10.1186/1479-5876-9-168; PMID: 21970318
   PubMed Web of Science ®Google Scholar
• Honnorat J, Viaccoz A. New concepts in paraneoplastic neurological syndromes. Rev Neurol (Paris) 2011; 167:729 - 36; http://dx.doi.org/10.1016/j.neurol.2011.08.001; PMID: 21890156
   PubMed Web of Science ®Google Scholar
• Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853 - 62; http://dx.doi.org/10.1182/blood-2011-01-329656; PMID: 21908423
   PubMed Web of Science ®Google Scholar
• Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326 - 33; http://dx.doi.org/10.4161/onci.18852; PMID: 22737608
   PubMed Web of Science ®Google Scholar
• Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6:979 - 86; PMID: 10741724
   PubMed Web of Science ®Google Scholar
• Andrade Filho PA, López-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 2010; 33:83 - 91; http://dx.doi.org/10.1097/CJI.0b013e3181b8f421; PMID: 19952953
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615 - 25; http://dx.doi.org/10.1038/nrc1669; PMID: 16034368
   PubMed Web of Science ®Google Scholar
• Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev 2006; 213:66 - 81; http://dx.doi.org/10.1111/j.1600-065X.2006.00438.x; PMID: 16972897
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines?. Oncoimmunology 2012; 1:579 - 80; http://dx.doi.org/10.4161/onci.20730; PMID: 22934249
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081 - 91; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722; PMID: 22237626
   PubMed Web of Science ®Google Scholar
• Defrance T, Taillardet M, Genestier L. T cell-independent B cell memory. Curr Opin Immunol 2011; 23:330 - 6; http://dx.doi.org/10.1016/j.coi.2011.03.004; PMID: 21482090
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351 - 60; http://dx.doi.org/10.1038/nrc2373; PMID: 18418403
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685 - 711; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040; PMID: 12615891
   PubMed Web of Science ®Google Scholar
• Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005; 6:280 - 6; http://dx.doi.org/10.1038/ni1165; PMID: 15685176
   PubMed Web of Science ®Google Scholar
• Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton RA, et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 2007; 26:629 - 41; http://dx.doi.org/10.1016/j.immuni.2007.03.016; PMID: 17509906
   PubMed Web of Science ®Google Scholar
• Zou T, Caton AJ, Koretzky GA, Kambayashi T. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and -independent interactions. J Immunol 2010; 185:2790 - 9; http://dx.doi.org/10.4049/jimmunol.0903740; PMID: 20686126
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Reverse Warburg: straight to cancer. Cell Cycle 2012; 11:1059; http://dx.doi.org/10.4161/cc.11.6.19746; PMID: 22343921
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Kroemer G. Past, present, and future of molecular and cellular oncology. Front Oncol 2011; 1:1; http://dx.doi.org/10.3389/fonc.2011.00001; PMID: 22655224
   PubMedGoogle Scholar
• Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490 - 500; http://dx.doi.org/10.1038/nri2785; PMID: 20559327
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162 - 74; http://dx.doi.org/10.1038/nri2506; PMID: 19197294
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253 - 68; http://dx.doi.org/10.1038/nri3175; PMID: 22437938
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451 - 83; http://dx.doi.org/10.1146/annurev.immunol.021908.132532; PMID: 19105661
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958 - 69; http://dx.doi.org/10.1038/nri2448; PMID: 19029990
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology 2012; 1 In press
   Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial Watch: Prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology 2012; 1 In press
   Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493 - 506; http://dx.doi.org/10.4161/onci.20459; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Huff V. Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11:111 - 21; http://dx.doi.org/10.1038/nrc3002; PMID: 21248786
   PubMed Web of Science ®Google Scholar
• Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85:426 - 9; http://dx.doi.org/10.1532/IJH97.06194; PMID: 17562620
   PubMed Web of Science ®Google Scholar
• Busse A, Letsch A, Scheibenbogen C, Nonnenmacher A, Ochsenreither S, Thiel E, et al. Mutation or loss of Wilms’ tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. J Transl Med 2010; 8:5; http://dx.doi.org/10.1186/1479-5876-8-5; PMID: 20092642
   PubMed Web of Science ®Google Scholar
• Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 2010; 55:352 - 5; http://dx.doi.org/10.1002/pbc.22522; PMID: 20582983
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113:6541 - 8; http://dx.doi.org/10.1182/blood-2009-02-202598; PMID: 19389880
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010; 95:1191 - 7; http://dx.doi.org/10.3324/haematol.2009.014704; PMID: 20081055
   PubMed Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111:1357 - 65; http://dx.doi.org/10.1182/blood-2007-07-099366; PMID: 17978170
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91:2459 - 66; PMID: 9516146
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003; 101:4607 - 10; http://dx.doi.org/10.1182/blood-2002-06-1925; PMID: 12576327
   PubMed Web of Science ®Google Scholar
• McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A 2008; 105:10131 - 6; http://dx.doi.org/10.1073/pnas.0803636105; PMID: 18645180
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787 - 94; http://dx.doi.org/10.1200/JCO.2010.33.3005; PMID: 21632504
   PubMed Web of Science ®Google Scholar
• Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11:4460 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-05-0250; PMID: 15958631
   PubMed Web of Science ®Google Scholar
• Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007; 109:77 - 83; http://dx.doi.org/10.1002/cncr.22389; PMID: 17133412
   PubMed Web of Science ®Google Scholar
• Meek DW, Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012; 324:126 - 32; http://dx.doi.org/10.1016/j.canlet.2012.05.011; PMID: 22634429
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874 - 85; http://dx.doi.org/10.1038/nrc2761; PMID: 19935676
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673 - 9; http://dx.doi.org/10.1016/S1074-7613(00)80066-7; PMID: 10403642
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102:571 - 6; http://dx.doi.org/10.1182/blood-2002-08-2554; PMID: 12576330
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624 - 32; http://dx.doi.org/10.1200/JCO.2002.06.171; PMID: 12039923
   PubMed Web of Science ®Google Scholar
• Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002; 99:2845 - 50; http://dx.doi.org/10.1182/blood.V99.8.2845; PMID: 11929774
   PubMed Web of Science ®Google Scholar
• Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003; 9:5559 - 65; PMID: 14654536
   PubMed Web of Science ®Google Scholar
• Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11:5900 - 11; http://dx.doi.org/10.1158/1078-0432.CCR-05-0559; PMID: 16115932
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553 - 64; http://dx.doi.org/10.1007/s00262-006-0145-7; PMID: 16491401
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Frayssinet P, Cuello-Carrión FD. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. Cell Stress Chaperones 2007; 12:33 - 43; http://dx.doi.org/10.1379/CSC-218R.1; PMID: 17441505
   PubMed Web of Science ®Google Scholar
• Meyer RG, Korn S, Micke P, Becker K, Huber C, Wölfel T, et al. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 2007; 58:88 - 94; http://dx.doi.org/10.1016/j.lungcan.2007.05.003; PMID: 17599645
   PubMed Web of Science ®Google Scholar
• Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108:963 - 71; http://dx.doi.org/10.3171/JNS/2008/108/5/0963; PMID: 18447714
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385; PMID: 21918169
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463 - 75; http://dx.doi.org/10.1038/nrc2656; PMID: 19536107
   PubMed Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10:760 - 74; http://dx.doi.org/10.1038/nrc2947; PMID: 20966921
   PubMed Web of Science ®Google Scholar
• Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19:713 - 23; http://dx.doi.org/10.1111/j.1750-3639.2009.00318.x; PMID: 19744042
   PubMed Web of Science ®Google Scholar
• Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135:1042 - 54; http://dx.doi.org/10.1093/brain/aws042; PMID: 22418738
   PubMed Web of Science ®Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10:371 - 4; http://dx.doi.org/10.3816/CLC.2009.n.052; PMID: 19808198
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118:2594 - 602; http://dx.doi.org/10.1002/cncr.26574; PMID: 21989902
   PubMed Web of Science ®Google Scholar
• Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6:24; http://dx.doi.org/10.1186/1479-5876-6-24; PMID: 18471305
   PubMed Web of Science ®Google Scholar
• Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17:3408 - 19; http://dx.doi.org/10.1158/1078-0432.CCR-10-2614; PMID: 21300761
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 2012; 23:338 - 45; http://dx.doi.org/10.1093/annonc/mdr154; PMID: 21543625
   PubMed Web of Science ®Google Scholar
• Jiang XP, Yang DC, Elliott RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 2000; 15:495 - 505; http://dx.doi.org/10.1089/cbr.2000.15.495; PMID: 11155821
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22:54 - 66; http://dx.doi.org/10.1097/00002371-199901000-00008; PMID: 9924700
   PubMed Web of Science ®Google Scholar
• Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, et al. Tumor antigens and markers for breast and ovarian cancers. Front Biosci 2002; 7:e48 - 57; http://dx.doi.org/10.2741/ghader; PMID: 11815284
   PubMed Web of Science ®Google Scholar
• MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother (1991) 1992; 11:292 - 305; http://dx.doi.org/10.1097/00002371-199205000-00008; PMID: 1599915
   PubMed Web of Science ®Google Scholar
• Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27:60 - 72; http://dx.doi.org/10.1097/00002371-200401000-00006; PMID: 14676634
   PubMed Web of Science ®Google Scholar
• Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer 2012; 131:E670 - 80; http://dx.doi.org/10.1002/ijc.27388; PMID: 22139992
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012; 109:5797 - 802; http://dx.doi.org/10.1073/pnas.1117208109; PMID: 22454499
   PubMed Web of Science ®Google Scholar
• Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, et al. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 2009; 208:193 - 201; http://dx.doi.org/10.1016/j.jamcollsurg.2008.10.018; PMID: 19228530
   PubMed Web of Science ®Google Scholar
• Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010; 16:3495 - 506; http://dx.doi.org/10.1158/1078-0432.CCR-10-0085; PMID: 20466887
   PubMed Web of Science ®Google Scholar
• Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J Immunother 2009; 32:655 - 66; http://dx.doi.org/10.1097/CJI.0b013e3181a80e0d; PMID: 19483644
   PubMed Web of Science ®Google Scholar
• Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006; 55:1033 - 42; http://dx.doi.org/10.1007/s00262-005-0090-x; PMID: 16283303
   PubMed Web of Science ®Google Scholar
• Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007; 7:9; PMID: 17441676
   PubMedGoogle Scholar
• Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007; 120:2178 - 84; http://dx.doi.org/10.1002/ijc.22583; PMID: 17278093
   PubMed Web of Science ®Google Scholar
• Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2012; 130:584 - 92; http://dx.doi.org/10.1002/ijc.26074; PMID: 21413013
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A 1999; 96:5710 - 5; http://dx.doi.org/10.1073/pnas.96.10.5710; PMID: 10318949
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004; 60:32 - 45; http://dx.doi.org/10.1002/pros.20011; PMID: 15129427
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004; 95:77 - 84; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03174.x; PMID: 14720331
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63:1 - 12; http://dx.doi.org/10.1002/pros.20157; PMID: 15378520
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003; 57:80 - 92; http://dx.doi.org/10.1002/pros.10276; PMID: 12886526
   PubMed Web of Science ®Google Scholar
• Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69:917 - 27; http://dx.doi.org/10.1002/pros.20941; PMID: 19267352
   PubMed Web of Science ®Google Scholar
• Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, et al. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 2010; 101:601 - 8; http://dx.doi.org/10.1111/j.1349-7006.2009.01459.x; PMID: 20128819
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74:193 - 8; http://dx.doi.org/10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F; PMID: 9133455
   PubMed Web of Science ®Google Scholar
• Wolfgang CD, Essand M, Lee B, Pastan I. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res 2001; 61:8122 - 6; PMID: 11719440
   PubMed Web of Science ®Google Scholar
• Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci U S A 2000; 97:9437 - 42; http://dx.doi.org/10.1073/pnas.160270597; PMID: 10931945
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 2006; 90:243 - 95; http://dx.doi.org/10.1016/S0065-2776(06)90007-8; PMID: 16730266
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7:3012 - 24; PMID: 11595689
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003; 9:1301 - 12; PMID: 12684398
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21:4016 - 26; http://dx.doi.org/10.1200/JCO.2003.10.005; PMID: 14581425
   PubMed Web of Science ®Google Scholar
• Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res 2004; 10:5004 - 13; http://dx.doi.org/10.1158/1078-0432.CCR-04-0241; PMID: 15297401
   PubMed Web of Science ®Google Scholar
• Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO, et al. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2005; 2:e265; http://dx.doi.org/10.1371/journal.pmed.0020265; PMID: 16162034
   PubMed Web of Science ®Google Scholar
• Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006; 29:352 - 60; http://dx.doi.org/10.1097/01.coc.0000217877.78473.a4; PMID: 16891861
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Reitz M. GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Cancer Biother Radiopharm 2007; 22:551 - 5; http://dx.doi.org/10.1089/cbr.2007.376; PMID: 17803450
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr., Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007; 179:4919 - 28; PMID: 17878392
   PubMed Web of Science ®Google Scholar
• Bins A, Mallo H, Sein J, van den Bogaard C, Nooijen W, Vyth-Dreese F, et al. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J Immunother 2007; 30:234 - 9; http://dx.doi.org/10.1097/01.cji.0000211333.06762.47; PMID: 17471170
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13:6386 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-07-0486; PMID: 17975151
   PubMed Web of Science ®Google Scholar
• Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009; 124:130 - 9; http://dx.doi.org/10.1002/ijc.23886; PMID: 18839429
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15:7036 - 44; http://dx.doi.org/10.1158/1078-0432.CCR-09-1544; PMID: 19903780
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, et al. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund’s adjuvant for multipeptide melanoma vaccines. J Immunother 2010; 33:630 - 8; http://dx.doi.org/10.1097/CJI.0b013e3181e311ac; PMID: 20551833
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119 - 27; http://dx.doi.org/10.1056/NEJMoa1012863; PMID: 21631324
   PubMed Web of Science ®Google Scholar
• Pittet MJ, Speiser DE, Liénard D, Valmori D, Guillaume P, Dutoit V, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001; 7:Suppl 796s - 803s; PMID: 11300475
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, et al. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003; 9:669 - 77; PMID: 12576434
   PubMed Web of Science ®Google Scholar
• Cebon J, Jäger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 3:7; PMID: 12862418
   PubMedGoogle Scholar
• Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, et al. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 2007; 30:240 - 50; http://dx.doi.org/10.1097/01.cji.0000211332.68643.98; PMID: 17471171
   PubMed Web of Science ®Google Scholar
• Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, et al. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J Immunother 2009; 32:875 - 83; http://dx.doi.org/10.1097/CJI.0b013e3181b56ad9; PMID: 19752746
   PubMed Web of Science ®Google Scholar
• Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, et al. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res 2011; 17:2987 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-10-3272; PMID: 21385924
   PubMed Web of Science ®Google Scholar
• Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, et al. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A 2011; 108:15318 - 23; http://dx.doi.org/10.1073/pnas.1105419108; PMID: 21876175
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000; 23:275 - 81; http://dx.doi.org/10.1097/00002371-200003000-00012; PMID: 10746554
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003; 104:188 - 94; http://dx.doi.org/10.1002/ijc.10961; PMID: 12569574
   PubMed Web of Science ®Google Scholar
• Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004; 27:472 - 7; http://dx.doi.org/10.1097/00002371-200411000-00007; PMID: 15534491
   PubMed Web of Science ®Google Scholar
• Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008; 31:781 - 91; http://dx.doi.org/10.1097/CJI.0b013e318183af0b; PMID: 18779741
   PubMed Web of Science ®Google Scholar
• Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, et al. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res 2009; 69:1046 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-08-2926; PMID: 19176376
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-11-0184; PMID: 21586625
   PubMed Web of Science ®Google Scholar
• Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004; 101:9363 - 8; http://dx.doi.org/10.1073/pnas.0403271101; PMID: 15197261
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101:10697 - 702; http://dx.doi.org/10.1073/pnas.0403572101; PMID: 15252201
   PubMed Web of Science ®Google Scholar
• Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007; 104:8947 - 52; http://dx.doi.org/10.1073/pnas.0703395104; PMID: 17517626
   PubMed Web of Science ®Google Scholar
• Cohen L, Parker PA, Sterner J, De Moor C. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res 2002; 12:505 - 11; http://dx.doi.org/10.1097/00008390-200209000-00013; PMID: 12394193
   PubMed Web of Science ®Google Scholar
• Dadaglio G, Morel S, Bauche C, Moukrim Z, Lemonnier FA, Van Den Eynde BJ, et al. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int Immunol 2003; 15:1423 - 30; http://dx.doi.org/10.1093/intimm/dxg144; PMID: 14645151
   PubMed Web of Science ®Google Scholar
• Motta I, André F, Lim A, Tartaglia J, Cox WI, Zitvogel L, et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 2001; 167:1795 - 802; PMID: 11466405
   PubMed Web of Science ®Google Scholar
• Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90:1334 - 42; http://dx.doi.org/10.1038/sj.bjc.6601711; PMID: 15054451
   PubMed Web of Science ®Google Scholar
• Tsuruma T, Torigoe T, Hata F, Furuhata T, Sato N, Hirata K. [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy]. Gan To Kagaku Ryoho 2004; 31:1634 - 6; PMID: 15553667
   PubMedGoogle Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55:1294 - 8; http://dx.doi.org/10.1007/s00262-005-0102-x; PMID: 16315030
   PubMed Web of Science ®Google Scholar
• Hattori T, Okuno K, Yoshida K, Kokubu T, Mine T, Yamada R, et al. [A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer]. Gan To Kagaku Ryoho 2006; 33:1745 - 7; PMID: 17212094
   PubMedGoogle Scholar
• Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, et al. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007; 98:1113 - 9; http://dx.doi.org/10.1111/j.1349-7006.2007.00498.x; PMID: 17459063
   PubMed Web of Science ®Google Scholar
• Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, et al. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2008; 123:2362 - 9; http://dx.doi.org/10.1002/ijc.23810; PMID: 18729190
   PubMed Web of Science ®Google Scholar
• Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012; 103:150 - 3; http://dx.doi.org/10.1111/j.1349-7006.2011.02106.x; PMID: 22221328
   PubMed Web of Science ®Google Scholar
• Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; http://dx.doi.org/10.1186/1479-5876-10-141; PMID: 22776426
   PubMed Web of Science ®Google Scholar
• Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100:1502 - 9; http://dx.doi.org/10.1111/j.1349-7006.2009.01200.x; PMID: 19459850
   PubMed Web of Science ®Google Scholar
• Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406 - 16; PMID: 10999722
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23:255 - 66; http://dx.doi.org/10.1097/00002371-200003000-00010; PMID: 10746552
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35:946 - 52; http://dx.doi.org/10.1016/S0959-8049(99)00048-9; PMID: 10533477
   PubMed Web of Science ®Google Scholar
• Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 2007; 98:1965 - 8; http://dx.doi.org/10.1111/j.1349-7006.2007.00631.x; PMID: 17919310
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; In press http://dx.doi.org/10.1038/nm.2883; PMID: 22842478
   PubMed Web of Science ®Google Scholar
• Hoffman ES, Smith RE, Renaud RC Jr.. From the analyst’s couch: TLR-targeted therapeutics. Nat Rev Drug Discov 2005; 4:879 - 80; http://dx.doi.org/10.1038/nrd1880; PMID: 16299917
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61 - 9; http://dx.doi.org/10.1007/s10555-011-9273-4; PMID: 21249425
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573 - 7; http://dx.doi.org/10.1126/science.1208347; PMID: 22174255
   PubMed Web of Science ®Google Scholar
• Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009; 58:1801 - 7; http://dx.doi.org/10.1007/s00262-009-0691-x; PMID: 19294381
   PubMed Web of Science ®Google Scholar
• Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 2011; 102:324 - 9; http://dx.doi.org/10.1111/j.1349-7006.2010.01789.x; PMID: 21143701
   PubMed Web of Science ®Google Scholar
• Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, et al. A phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006; 36:231 - 6; http://dx.doi.org/10.1093/jjco/hyl005; PMID: 16611662
   PubMed Web of Science ®Google Scholar
• Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 2006; 12:7397 - 405; http://dx.doi.org/10.1158/1078-0432.CCR-06-1546; PMID: 17189412
   PubMed Web of Science ®Google Scholar
• Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27:5270 - 7; http://dx.doi.org/10.1200/JCO.2009.22.3883; PMID: 19752336
   PubMed Web of Science ®Google Scholar
• Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97:12198 - 203; http://dx.doi.org/10.1073/pnas.220413497; PMID: 11027314
   PubMed Web of Science ®Google Scholar
• Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000; 49:517 - 29; http://dx.doi.org/10.1007/s002620000145; PMID: 11129322
   PubMed Web of Science ®Google Scholar
• Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000; 88:232 - 8; http://dx.doi.org/10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8; PMID: 11004674
   PubMed Web of Science ®Google Scholar
• Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, et al. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997; 182:137 - 51; http://dx.doi.org/10.1006/cimm.1997.1224; PMID: 9514698
   PubMed Web of Science ®Google Scholar
• Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10:929 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-1117-3; PMID: 14871969
   PubMed Web of Science ®Google Scholar
• Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999; 22:155 - 65; http://dx.doi.org/10.1097/00002371-199903000-00007; PMID: 10093040
   PubMed Web of Science ®Google Scholar
• Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother 2003; 26:357 - 66; http://dx.doi.org/10.1097/00002371-200307000-00008; PMID: 12843798
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14:169 - 77; http://dx.doi.org/10.1158/1078-0432.CCR-07-1881; PMID: 18172268
   PubMed Web of Science ®Google Scholar
• Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, et al. Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Rev Vaccines 2012; 11:721 - 31; http://dx.doi.org/10.1586/erv.12.39; PMID: 22873128
   PubMed Web of Science ®Google Scholar
• Levy A, Massard C, Gross-Goupil M, Fizazi K. Carcinomas of an unknown primary site: a curable disease?. Ann Oncol 2008; 19:1657 - 8; http://dx.doi.org/10.1093/annonc/mdn430; PMID: 18647966
   PubMed Web of Science ®Google Scholar
• Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012; 37:1 - 2; http://dx.doi.org/10.1016/j.immuni.2012.07.010; PMID: 22840835
   PubMed Web of Science ®Google Scholar
• Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2011; 60:15 - 22; http://dx.doi.org/10.1007/s00262-010-0940-z; PMID: 21080166
   PubMed Web of Science ®Google Scholar
• Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al. “MIATA”-minimal information about T cell assays. Immunity 2009; 31:527 - 8; http://dx.doi.org/10.1016/j.immuni.2009.09.007; PMID: 19833080
   PubMed Web of Science ®Google Scholar